DrugPatentWatch Database Preview
Drugs in Development Information for BCT197
» See Plans and Pricing
What is the drug development status for BCT197?
BCT197 is an investigational drug.
There have been 5 clinical trials for BCT197.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2016.
The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, and Lung Diseases. The leading clinical trial sponsors are Mereo BioPharma, Novartis Pharmaceuticals, and [disabled in preview].
There are eight US patents protecting this investigational drug and one hundred and thirty international patents.
Summary for BCT197
| US Patents | 8 |
| International Patents | 130 |
| US Patent Applications | 15 |
| WIPO Patent Applications | 47 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2016-04-01) |
| Vendors | 19 |
Recent Clinical Trials for BCT197
| Title | Sponsor | Phase |
|---|---|---|
| The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants | Mereo BioPharma | Phase 1 |
| The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers | Mereo BioPharma | Phase 1 |
| Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease | Mereo BioPharma | Phase 2 |
Clinical Trial Summary for BCT197
Top disease conditions for BCT197
Top clinical trial sponsors for BCT197
US Patents for BCT197
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| BCT197 | Start Trial | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (Cambridge, MA) | Start Trial |
| BCT197 | Start Trial | Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease | MEREO BIOPHARMA 1 LIMITED (London, GB) | Start Trial |
| BCT197 | Start Trial | 5-membered heterocycle-based p38 kinase inhibitors | Novartis AG (Basel, CH) | Start Trial |
| BCT197 | Start Trial | 5-membered heterocycle-based p38 kinase inhibitors | Novartis AG (Basel, CH) | Start Trial |
| BCT197 | Start Trial | 5-membered heterocycle-based P38 kinase inhibitors | Novartis AG (Basel, CH) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BCT197
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| BCT197 | Australia | AU2018346709 | 2037-10-05 | Start Trial |
| BCT197 | Australia | AU2018346712 | 2037-10-05 | Start Trial |
| BCT197 | Canada | CA3077499 | 2037-10-05 | Start Trial |
| BCT197 | Canada | CA3078232 | 2037-10-05 | Start Trial |
| BCT197 | Colombia | CO2020005351 | 2037-10-05 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
